Prestigious Recognitions, Financial Results, Presentations, Study Analysis, and SEC Filings - Analyst Notes on WellPoint, NPS Pharma, Novartis, Cigna and Forest

NEW YORK, May 13, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Novartis AG (NYSE: NVS), Cigna Corp. (NYSE: CI) and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2384-100free.

WellPoint Inc. Analyst Notes
On May 5, 2014, WellPoint Inc. (WellPoint) reported that it has been recognized for the second time for its work in making certain materials for its affiliated Medicare plans easier for members to understand. WellPoint's Medicare Marketing Regulated Communications Team was awarded a ClearMark "Award of Distinction" from the Center for Plain Language for its work on the WellPoint affiliated version of Medicare's Evidence of Coverage (EOC). Marc Russo, President of WellPoint's Medicare programs, commented, "Medicare can be complicated. Making it less complicated is part of our core mission of being easy to do business with." The full analyst notes on WellPoint are available to download free of charge at:

http://www.analystsreview.com/2384-WLP-13May2014.pdf

NPS Pharmaceuticals, Inc. Analyst Notes
On May 8, 2014, NPS Pharmaceuticals, Inc. (NPS Pharma) reported its financial results for Q1 2014. The Company posted 73.2% YoY increase in total revenues to $44 million, which were lower than Zacks consensus revenue estimate of $54 million. Net loss for Q1 2014 came in at $6.6 million, or $0.06 per diluted share, versus $7.8 million, or $0.09 per diluted share in Q1 2013. Zacks consensus diluted EPS estimate for the quarter was $0.04. The Company revised its full-year 2014 Gattex/Revestive net sales guidance to a range of $100 to $110 million from previous net sales guidance of $110 million to $120 million. The Company's stock ended 10.6% lower, to close the day at $24.17. The full analyst notes on NPS Pharma are available to download free of charge at:

http://www.analystsreview.com/2384-NPSP-13May2014.pdf

Novartis AG Analyst Notes
On May 9, 2014, Novartis AG (Novartis) reported the presentation of data on the eye drug Lucentis® (ranibizumab), first licensed in June 2006, at the 2014 Association for Research in Vision and Ophthalmology (ARVO) annual meeting. The Company stated that the work spans the five indications that Lucentis is licensed for (treatment of: wet age-related macular degeneration, visual impairment due to diabetic macular edema, branch retinal vein occlusion, central retinal vein occlusion and myopic choroidal neovascularization), and highlights the effectiveness and safety profile of Lucentis through both pivotal clinical trials and real-world observational studies. Dr Timothy Wright, Global Head Development, Novartis Pharma AG, commented, "Lucentis has already shown proven effectiveness in reducing vision loss across indications, and this is evident by the clinical trial findings presented at ARVO 2014. What is key is that the efficacy and safety findings are also reflected in the real world clinical setting." The full analyst notes on Novartis are available to download free of charge at:

http://www.analystsreview.com/2384-NVS-13May2014.pdf

Cigna Corp. Analyst Notes
On May 5, 2014, Cigna Corp. (Cigna) released the results of an analysis of 20 years of Cigna's short-term disability claims. The analysis highlights that the absence related to obesity, treatment for skin cancer and herniated disc surgery increased significantly from 1993 to 2012, whereas a reduction in absences related to depression coupled with an increase in prescribed anti-depressants may signal a hidden problem. Dr. Robert Anfield, Chief Medical Officer for Cigna's Disability Insurance Unit, commented, "Employers who focus on productivity as an outcome will succeed in the future. Though medical advances have helped improve the quality of life for many people, lifestyle and behavioral factors remain key drivers of absence." The results also indicated that the claims related to obesity and skin cancer have increased dramatically over the last 20 years. Also, that there has been 45% increase in absences due to the surgical treatment of herniated discs. The full analyst notes on Cigna are available to download free of charge at:

http://www.analystsreview.com/2384-CI-13May2014.pdf

Forest Laboratories Inc. Analyst Notes
On May 5, 2014, Forest Laboratories Inc. (Forest) reported that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission (SEC) by Actavis plc (Actavis) on March 25, 2014 and amended on May 2, 2014 (Form S-4), which includes a joint proxy statement of Actavis and Forest, was declared effective on May 2, 2014. The Form S-4 is accessible on the SEC's EDGAR system. The Company also informed that its special meeting of shareholders will be held on June 17, 2014 at 8:30 a.m. local time, at J.P. Morgan, 270 Park Avenue, New York to seek shareholders' approval in connection with the merger and related matters. The full analyst notes on Forest are available to download free of charge at:

http://www.analystsreview.com/2384-FRX-13May2014.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystsreview.com/

SOURCE Analysts Review